Method for the treatment of residual symptoms of schizophrenia
US9956227B2 · kind B2 · utility
63Cited by
80References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 3, 2014 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Dec 3, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.